L P Aiello

Summary

Affiliation: Harvard University
Country: USA

Publications

  1. ncbi Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy
    L P Aiello
    Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA
    Eye (Lond) 18:117-25. 2004
  2. ncbi Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy
    Lloyd Paul Aiello
    Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Ophthalmology 113:2221-30. 2006
  3. ncbi Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibit
    Lloyd Paul Aiello
    Joslin Diabetes Center, Beetham Eye Institute, Department of Ophthalmology, Harvard University Medical School, Boston, Massachusetts, USA
    Retina 31:2084-94. 2011
  4. ncbi Systemic considerations in the management of diabetic retinopathy
    L P Aiello
    Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Am J Ophthalmol 132:760-76. 2001
  5. ncbi Role of vascular endothelial growth factor in diabetic vascular complications
    L P Aiello
    Beetham Eye Institute and Division of Vascular Cell Biology, Joslin Diabetes Center, Boston, Massachusetts, 02215, USA
    Kidney Int Suppl 77:S113-9. 2000
  6. ncbi von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes
    D Feng
    Institute for Prevention of Cardiovascular Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Diabetes Care 23:1694-8. 2000
  7. ncbi Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies
    L P Aiello
    Harvard Medical School, Department of Ophthalmology, Boston, Mass, USA
    Ophthalmic Res 29:354-62. 1997
  8. ncbi The potential role of PKC beta in diabetic retinopathy and macular edema
    Lloyd Paul Aiello
    Harvard Medical School and Joslin Diabetes Center, Boston, Massachussetts, USA
    Surv Ophthalmol 47:S263-9. 2002
  9. ncbi Ruboxistaurin mesilate hydrate for diabetic retinopathy
    Stephen G Schwartz
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Naples, FL, USA
    Drugs Today (Barc) 45:269-74. 2009
  10. ncbi Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients
    Lloyd Paul Aiello
    Beetham Eye Institute and Eye Research Section, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Invest Ophthalmol Vis Sci 47:86-92. 2006

Research Grants

  1. Diabetic Retinopathy Clinical Research Network
    Lloyd Aiello; Fiscal Year: 2005

Detail Information

Publications46

  1. ncbi Growth factors and protein kinase C inhibitors as novel therapies for the medical management diabetic retinopathy
    L P Aiello
    Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA
    Eye (Lond) 18:117-25. 2004
    ..Pharmacological manipulation of protein kinase C and various growth factors may form the basis of future treatments for diabetic retinopathy...
  2. ncbi Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy
    Lloyd Paul Aiello
    Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Ophthalmology 113:2221-30. 2006
    ..To evaluate the effect of ruboxistaurin, an orally administered protein kinase C beta (PKC beta) isozyme-selective inhibitor, on vision loss in patients with diabetes...
  3. ncbi Oral protein kinase c β inhibition using ruboxistaurin: efficacy, safety, and causes of vision loss among 813 patients (1,392 eyes) with diabetic retinopathy in the Protein Kinase C β Inhibitor-Diabetic Retinopathy Study and the Protein Kinase C β Inhibit
    Lloyd Paul Aiello
    Joslin Diabetes Center, Beetham Eye Institute, Department of Ophthalmology, Harvard University Medical School, Boston, Massachusetts, USA
    Retina 31:2084-94. 2011
    ....
  4. ncbi Systemic considerations in the management of diabetic retinopathy
    L P Aiello
    Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, MA 02215, USA
    Am J Ophthalmol 132:760-76. 2001
    ....
  5. ncbi Role of vascular endothelial growth factor in diabetic vascular complications
    L P Aiello
    Beetham Eye Institute and Division of Vascular Cell Biology, Joslin Diabetes Center, Boston, Massachusetts, 02215, USA
    Kidney Int Suppl 77:S113-9. 2000
    ..This is particularly true with regard to retinal vascular disease and the role of the angiogenesis- and vasopermeability-inducing molecule, vascular endothelial growth factor (VEGF)...
  6. ncbi von Willebrand factor and retinal circulation in early-stage retinopathy of type 1 diabetes
    D Feng
    Institute for Prevention of Cardiovascular Disease, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    Diabetes Care 23:1694-8. 2000
    ..Because von Willebrand factor (vWF) is a marker for endothelial dysfunction and mediates platelet adhesion, we determined if there was an association between vWF and retinal circulation in the early stages of diabetic retinopathy...
  7. ncbi Vascular endothelial growth factor and the eye: biochemical mechanisms of action and implications for novel therapies
    L P Aiello
    Harvard Medical School, Department of Ophthalmology, Boston, Mass, USA
    Ophthalmic Res 29:354-62. 1997
    ..The recent insights into the mechanisms of intraocular angiogenesis have provided new targets for novel nondestructive therapeutic agents directed toward preventing the visual loss associated with ophthalmic neovascular disorders...
  8. ncbi The potential role of PKC beta in diabetic retinopathy and macular edema
    Lloyd Paul Aiello
    Harvard Medical School and Joslin Diabetes Center, Boston, Massachussetts, USA
    Surv Ophthalmol 47:S263-9. 2002
    ..The status of ongoing clinical trials aimed at addressing the efficacy of PKC beta with regard to diabetes-induced retinal complications and perspectives on the role of PKC beta are presented...
  9. ncbi Ruboxistaurin mesilate hydrate for diabetic retinopathy
    Stephen G Schwartz
    Department of Ophthalmology, Bascom Palmer Eye Institute, University of Miami Miller School of Medicine, Naples, FL, USA
    Drugs Today (Barc) 45:269-74. 2009
    ..The U.S. Food and Drug Administration issued an approvable letter for ruboxistaurin in 2006, but at this time the medication is not available for routine clinical use...
  10. ncbi Inhibition of PKC beta by oral administration of ruboxistaurin is well tolerated and ameliorates diabetes-induced retinal hemodynamic abnormalities in patients
    Lloyd Paul Aiello
    Beetham Eye Institute and Eye Research Section, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Invest Ophthalmol Vis Sci 47:86-92. 2006
    ..To assess ocular and systemic safety and pharmacodynamic effects of the oral PKC beta selective inhibitor ruboxistaurin (RBX; LY333531) mesylate in patients with diabetes...
  11. ncbi Protection from retinopathy and other complications in patients with type 1 diabetes of extreme duration: the joslin 50-year medalist study
    Jennifer K Sun
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, USA
    Diabetes Care 34:968-74. 2011
    ..Characterization of a complication-free subgroup in this cohort would suggest that some individuals are protected from diabetes complications and allow identification of endogenous protective factors...
  12. ncbi Integrin-mediated neutrophil adhesion and retinal leukostasis in diabetes
    F C Barouch
    Laboratory for Surgical Research, Children s Hospital, Boston, Massachusetts, USA
    Invest Ophthalmol Vis Sci 41:1153-8. 2000
    ..In vivo, CD18 blockade significantly decreases leukostasis in the diabetic retinal microvasculature. Integrin adhesion molecules may serve as therapeutic targets for the treatment and/or prevention of early diabetic retinopathy...
  13. ncbi Hepatocyte growth factor induces retinal vascular permeability via MAP-kinase and PI-3 kinase without altering retinal hemodynamics
    Allen C Clermont
    Section of Eye Research and Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Invest Ophthalmol Vis Sci 47:2701-8. 2006
    ..Thus, HGF may represent another clinically significant contributor to retinal edema distinct from the actions of VEGF...
  14. ncbi Diabetic retinopathy
    J S Wong
    Beetham Eye Institute, Joslin Diabetes Center, Boston, USA
    Ann Acad Med Singapore 29:745-52. 2000
    ..To provide a review of the current standard of care in diabetic eye management...
  15. ncbi Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy
    S E Bursell
    Beetham Eye Institute, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02115, USA
    Ophthalmology 108:572-85. 2001
    ....
  16. ncbi Factors associated with improvement and worsening of visual acuity 2 years after focal/grid photocoagulation for diabetic macular edema
    Lloyd Paul Aiello
    Joslin Diabetes Center and Department of Ophthalmology, Harvard Medical School, Cambridge, Massachusetts, USA
    Ophthalmology 117:946-53. 2010
    ..net) trial comparing triamcinolone with focal/grid laser...
  17. ncbi Identification of multiple genes in bovine retinal pericytes altered by exposure to elevated levels of glucose by using mRNA differential display
    L P Aiello
    Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215
    Proc Natl Acad Sci U S A 91:6231-5. 1994
    ..In addition, this study provides strong support for the use of differential mRNA display as a method to rapidly isolate differentially expressed genes in metabolic systems...
  18. ncbi Characterization of protein kinase C beta isoform's action on retinoblastoma protein phosphorylation, vascular endothelial growth factor-induced endothelial cell proliferation, and retinal neovascularization
    Kiyoshi Suzuma
    Research Division, Joslin Diabetes Center, Boston, MA 02215, USA
    Proc Natl Acad Sci U S A 99:721-6. 2002
    ..The potential functional consequences of PKC beta-induced retinoblastoma phosphorylation could include enhanced E2 promoter binding factor transcriptional activity and increased VEGF-induced endothelial cell proliferation...
  19. ncbi Effect of systemic medications on onset and progression of diabetic retinopathy
    Paolo S Silva
    Beetham Eye Institute, Joslin Diabetes Center, Department of Ophthalmology, Harvard Medical School, 1 Joslin Place, Boston, MA 02215, USA
    Nat Rev Endocrinol 6:494-508. 2010
    ..Thus, these compounds must undergo further rigorous study to determine the actual clinical efficacy and adverse effects before definitive therapeutic care recommendations can be offered...
  20. ncbi Rapid and durable recovery of visual function in a patient with von hippel-lindau syndrome after systemic therapy with vascular endothelial growth factor receptor inhibitor su5416
    Lloyd Paul Aiello
    Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Place, Boston, Massachusetts 02115, USA
    Ophthalmology 109:1745-51. 2002
    ..These findings suggest that continued evaluation of VEGF inhibitors for ocular neovascular disorders is warranted...
  21. ncbi Suppression of Fas-FasL-induced endothelial cell apoptosis prevents diabetic blood-retinal barrier breakdown in a model of streptozotocin-induced diabetes
    Antonia M Joussen
    Retina Research Institute, Massachusetts Eye and Ear Infirmary, Harvard Medical School, Boston, Massachusetts 02114, USA
    FASEB J 17:76-8. 2003
    ..These data imply that the targeting of the Fas-FasL pathway may prove beneficial in the treatment of diabetic retinopathy...
  22. ncbi Clinical factors associated with resistance to microvascular complications in diabetic patients of extreme disease duration: the 50-year medalist study
    Hillary A Keenan
    Joslin Diabetes Center, One Joslin Place, Boston, MA 02215, USA
    Diabetes Care 30:1995-7. 2007
  23. ncbi Stretch-induced retinal vascular endothelial growth factor expression is mediated by phosphatidylinositol 3-kinase and protein kinase C (PKC)-zeta but not by stretch-induced ERK1/2, Akt, Ras, or classical/novel PKC pathways
    Izumi Suzuma
    Research Division and Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    J Biol Chem 277:1047-57. 2002
    ..This mechanism may play a role in the well documented association of concomitant hypertension with clinical exacerbation of neovascularization and vascular permeability...
  24. ncbi Congenital retinal macrovessel
    Rama D Jager
    Beetham Eye Institute, Joslin Diabetes Center, Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA
    Retina 25:538-40. 2005
  25. ncbi Comparison of nonmydriatic digital retinal imaging versus dilated ophthalmic examination for nondiabetic eye disease in persons with diabetes
    Sing-Pey Chow
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Ophthalmology 113:833-40. 2006
    ....
  26. ncbi Telemedicine and diabetic retinopathy: moving beyond retinal screening
    Paolo S Silva
    Department of Ophthalmology, Harvard Medical School and Beetham Eye Institute, Joslin Diabetes Center, 1 Joslin Pl, Boston, MA 02215, USA
    Arch Ophthalmol 129:236-42. 2011
    ..In addition, such programs will allow the rapid transfer of clinically relevant discoveries and will allow a considerably larger benefit to a broader patient population...
  27. ncbi Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy
    Ben Bo Gao
    Research Division, Beetham Eye Institute, Joslin Diabetes Center, One Joslin Place, Boston, Massachusetts 02215, USA
    J Proteome Res 7:2516-25. 2008
    ..These data provide an in depth analysis of the human vitreous proteome and reveal protein alterations that are associated with PDR...
  28. ncbi Effects of dilation on electronic-ETDRS visual acuity in diabetic patients
    Jennifer K Sun
    Beetham Eye Institute and Eye Research Section, Joslin Diabetes Center, Boston, Massachusetts, USA
    Invest Ophthalmol Vis Sci 50:1580-4. 2009
    ..To evaluate the effect of pupillary dilation on electronic-ETDRS visual acuity (EVA) in diabetic subjects and to assess postdilation EVA as a surrogate for predilation VA...
  29. ncbi Role of steroids in the management of diabetic macular edema and proliferative diabetic retinopathy
    Paolo S Silva
    Beetham Eye Institute and Section of Eye Research, Joslin Diabetes Center and Department of Ophthalmology, Harvard Medical School, Boston, MA 02215, USA
    Semin Ophthalmol 24:93-9. 2009
    ..The exact role of steroids in the treatment for diabetic retinopathy and macular edema remains to be fully elucidated...
  30. ncbi Extracellular carbonic anhydrase mediates hemorrhagic retinal and cerebral vascular permeability through prekallikrein activation
    Ben Bo Gao
    Research Division, Joslin Diabetes Center, One Joslin Place, Harvard Medical School, Boston, Massachusetts 02215, USA
    Nat Med 13:181-8. 2007
    ..Inhibition of extracellular CA-I and kallikrein-mediated innate inflammation could provide new therapeutic opportunities for the treatment of hemorrhage-induced retinal and cerebral edema...
  31. ncbi Bactericidal/permeability-increasing protein's signaling pathways and its retinal trophic and anti-angiogenic effects
    Michiko Yamagata
    Research Division, Joslin Diabetes Center, Harvard Medical School, Boston, Massachusetts 02215, USA
    FASEB J 20:2058-67. 2006
    ....
  32. ncbi Differential effects of bactericidal/permeability-increasing protein (BPI) analogues on retinal neovascularization and retinal pericyte growth
    Ravi K Rauniyar
    Research Division, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Invest Ophthalmol Vis Sci 43:503-9. 2002
    ..These data suggest that BPI-derived compounds may have unique therapeutic potential for proliferative retinal diseases such as diabetic retinopathy, if physiological levels can be achieved in clinical settings...
  33. ncbi Use of Joslin Vision Network digital-video nonmydriatic retinal imaging to assess diabetic retinopathy in a clinical program
    Anthony A Cavallerano
    Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA
    Retina 23:215-23. 2003
    ..Nondiabetic ocular pathology was identified. JVN assessment of DR level compares favorably to clinical practice, potentially improving access to eye care and enhancing diabetes management...
  34. ncbi Nonmydriatic digital imaging alternative for annual retinal examination in persons with previously documented no or mild diabetic retinopathy
    Jerry D Cavallerano
    Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts 02215, USA
    Am J Ophthalmol 140:667-73. 2005
    ..JVN digital imaging may be a suitable alternative for annual dilated retinal examination for determining level of DR or DME and appropriate follow-up comprehensive ophthalmic examination...
  35. ncbi A telemedicine program for diabetic retinopathy in a Veterans Affairs Medical Center--the Joslin Vision Network Eye Health Care Model
    Anthony A Cavallerano
    Beetham Eye Institute, Joslin Diabetes Center, Boston, MA 02215, USA
    Am J Ophthalmol 139:597-604. 2005
    ..6%) were ungradable for DME alone. CONCLUSION: In a non-ophthalmic setting, JVN identifies the severity of DR and nondiabetic ocular conditions, permitting appropriate triage for eye care...
  36. ncbi Rosiglitazone and delayed onset of proliferative diabetic retinopathy
    Lucy Q Shen
    Harvard Medical School, USA
    Arch Ophthalmol 126:793-9. 2008
    ....
  37. ncbi Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema
    Matthew D Davis
    Department of Ophthalmology and Visual Sciences, University of Wisconsin, Madison, WI, USA
    Invest Ophthalmol Vis Sci 49:1745-52. 2008
    ..To explore the correlation between optical coherence tomography (OCT) and stereoscopic fundus photographs (FP) for the assessment of retinal thickening (RT) in diabetic macular edema (DME) within a clinical trial...
  38. ncbi Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema
    Donald S Fong
    Arch Ophthalmol 125:469-80. 2007
    ..APPLICATION TO CLINICAL PRACTICE: Modified ETDRS focal photocoagulation should continue to be a standard approach for treating diabetic macular edema. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT00071773...
  39. ncbi Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema
    Magdalena G Krzystolik
    Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
    Ophthalmology 114:1520-5. 2007
    ..To evaluate optical coherence tomography (OCT) reproducibility in patients with diabetic macular edema (DME)...
  40. ncbi Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema
    Ronald P Danis
    Jaeb Center for Health Research, Tampa, FL 33647, USA
    Arch Ophthalmol 124:1701-7. 2006
    ..To evaluate diurnal variation in retinal thickness measured with optical coherence tomography (OCT) in patients with center-involved diabetic macular edema...
  41. ncbi Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema
    David J Browning
    Jaeb Center for Health Research, 15310 Amberly Drive, Suite 350, Tampa, FL 33647, USA
    Ophthalmology 114:525-36. 2007
    ..To compare optical coherence tomography (OCT)-measured retinal thickness and visual acuity in eyes with diabetic macular edema (DME) both before and after macular laser photocoagulation...
  42. ncbi Effect of ruboxistaurin on blood-retinal barrier permeability in relation to severity of leakage in diabetic macular edema
    Charlotte Strøm
    Department of Ophthalmology, Herlev Hospital, University of Copenhagen, Denmark
    Invest Ophthalmol Vis Sci 46:3855-8. 2005
    ....
  43. ncbi Decreased cardiac expression of vascular endothelial growth factor and its receptors in insulin-resistant and diabetic States: a possible explanation for impaired collateral formation in cardiac tissue
    Eva Chou
    Research Division, Beetham Eye Institute, Joslin Diabetes Center, Boston, Massachusetts, USA
    Circulation 105:373-9. 2002
    ..These results provide a potential explanation for concomitant capillary leakage and neovascularization in the retina and inadequate collateral formation in the myocardium of insulin-resistant and diabetic patients...
  44. ncbi Angiogenic pathways in diabetic retinopathy
    Lloyd Paul Aiello
    N Engl J Med 353:839-41. 2005
  45. ncbi Promoter polymorphism of the erythropoietin gene in severe diabetic eye and kidney complications
    Zongzhong Tong
    Department of Ophthalmology and Visual Sciences, Eccles Institute of Human Genetics
    Proc Natl Acad Sci U S A 105:6998-7003. 2008
    ..These results suggest that rs1617640 in the EPO promoter is significantly associated with PDR and ESRD. This study identifies a disease risk-associated gene and potential pathway mediating severe diabetic microvascular complications...

Research Grants2

  1. Diabetic Retinopathy Clinical Research Network
    Lloyd Aiello; Fiscal Year: 2005
    ..This proposal details the manner in which the specific goals of the network will be fostered under the guidance of the Study Chair. ..